Lixte Biotechnology Holdings, Inc.

Climate Impact & Sustainability Data (2015, 2023)

The Company has not yet commenced any sustainable revenue-generating operations, does not have any positive cash flows from operations, and is dependent on equity capital to fund its operating requirements.
The Company has experienced recurring losses and negative operating cash flows since inception, and has financed its working capital requirements through the recurring sale of its equity securities.
The Company does not have sufficient resources to fully develop and commercialize any products that may arise from its research.
The development process necessary to obtain regulatory approval is lengthy, complex and costly.

The Company will need to raise additional funds to fully develop and commercialize any products.
The Company is attempting to raise an additional approximately $3,000,000 of capital in 2016, likely in the form of equity, to also conduct a Phase 1b/2 clinical trial of LB-100 in combination with a platinum compound in platinum-resistant ovarian cancer and to extend the Company’s pre-clinical research to develop oral versions of its lead anti-phosphatase compounds.

Need for additional capital to fund operations and complete product development.
Substantial losses since inception and anticipated continued losses.
Substantial doubt about the Company’s ability to continue as a going concern.
Difficulties in enrolling patients in clinical trials.
Uncertain outcome of clinical trials.
Risks associated with operating in foreign countries.
Potential for undesirable side effects or other properties that could delay or prevent regulatory approval.
Dependence on third parties for clinical trials and manufacturing.
Competition from other companies with greater resources.
Potential for cybersecurity threats.
Difficulties in managing future growth.
Inadequate funding for FDA and other government agencies.
Unstable market and economic conditions.
Reduced reporting and disclosure requirements as a smaller reporting company.

Considering various strategies to obtain additional capital.
Seeking strategic partnerships.
Implementing a program to balance patent prosecution costs with intellectual property protection benefits.
Adding additional sites to clinical trials to increase patient accrual.
Obtaining product liability insurance.
Investing in cybersecurity policies and processes.
Developing plans to manage future growth.
Monitoring geopolitical risks and adjusting business plans accordingly.